Browsing Tag
Eli Lilly and Company
160 posts
IHL-42X screening begins as Incannex Healthcare enters a faster-moving oral sleep apnea race
Incannex Healthcare begins IHL-42X screening as cash, buybacks and Apnimed’s FDA filing reshape the oral sleep apnea investment case.
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
MedPal AI raises £5m as MPAL buys eMAR software and backs oral Wegovy launch
MedPal AI is combining pharmacy dispensing, care-home medication software and a private weight-loss clinic, but a 25% share-count expansion raises the execution bar.
Takeda is paying Insilico $600m to find drugs before humans take over
Takeda signs a $600 million Insilico AI drug deal. Read how Pharma.AI could reshape pipeline economics, R&D productivity and investor sentiment.
Eli Lilly ($LLY) surges past $1.07tn as EU oncology win and Medicare GLP-1 program align with analyst upgrade
Eli Lilly NYSE LLY surges 6.3 percent to record $1,208.12 on EU Jaypirca approval, Medicare GLP-1 Bridge Program and Leerink price target raise. Read more.
Could one hair loss antibody make Absci’s AI drug platform harder to ignore?
Absci’s ABS-201 data and $100 million raise sharpen ABSI’s AI biologics story across androgenetic alopecia, endometriosis and platform validation.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.
Could Ebglyss’ longer dosing window strengthen Eli Lilly and Company’s dermatology growth strategy?
Find out how Ebglyss’ every-eight-week FDA approval could strengthen Eli Lilly’s dermatology strategy and investor sentiment.